Twist Bioscience 10-Qquarter ended 2026-06-30

Executive Summary

Twist Bioscience delivered strong Q3 FY2026 growth, with revenue up 23% Y/Y as rising gene shipments, therapeutics demand, and DNA synthesis and protein solutions expanded the platform beyond its historically larger NGS business. Scale and process improvements lifted YTD gross margin, but SG&A growth continued to outpace revenue, widening the operating loss and demonstrating that commercial momentum has not yet produced operating leverage. Liquidity remains adequate for at least 12 months, according to management, but cash and investments fell to $166.8M while capital spending, lease commitments, strategic investments, and stock-based compensation increase funding and dilution risk. The investment case rests on whether volume growth, automation, and a richer therapeutics mix can convert into sustained margin expansion before the company needs to use its new $200.0M ATM program.

Key Financial Highlights

• Revenue mix: DNA synthesis and protein solutions rose 39% Y/Y to $56.6M in Q3 and reached 48% of revenue vs 43%; NGS grew 12% to $61.8M but its YTD mix fell to 52% from 56%, signaling diversification toward synthetic biology and biopharma.
• Operating scale: Q3 genes shipped increased 56% to ≈369,000 and customers rose to ≈2,664 from 2,484; shipment growth materially exceeded revenue growth, making pricing, product mix, and unit-cost improvements critical to future margins.
• Expense structure: YTD SG&A increased 24% to $226.5M, driven by headcount, commercial infrastructure, IT, marketing, and professional services; management expects Q4 savings, but this must translate into slower expense growth to establish operating leverage.
• Cash flow and investment: YTD operating cash outflow increased to $41.3M, while investing outflow reached $32.8M, including $27.6M of capex and a $5.0M asset acquisition; inventory and receivables also increased with expected demand and collection timing.
• Equity compensation: YTD stock-based compensation was $50.4M, with another $125.2M unrecognized across standard and performance-based units; the expense supports reported cash flow but creates persistent dilution, with 6.1M potential shares excluded from diluted EPS.
• Capital access and obligations: No shares had been sold under the new $200.0M ATM at quarter-end; liabilities include $93.6M of operating leases and a $15.0M future-revenue-sale obligation, limiting the economic benefit of headline liquidity.

Business Developments

Therapeutics became the principal growth engine, increasing 49% Y/Y to $40.4M in Q3 and reaching 34% of quarterly revenue vs 28%. Diagnostics remained the largest Q3 end market at $43.8M, but its mix fell to 37% from 40%; this shift supports management’s strategy of combining DNA synthesis, protein expression, antibody discovery, and NGS capabilities for biopharma customers.

Twist committed $33.8M to Invenra, comprising a seven-year co-exclusive license to the B-Body bispecific antibody discovery platform and a 6.24% fully diluted equity stake. Only $5.0M was paid in cash, with $28.8M settled or expected in Twist stock; the structure conserves liquidity and expands biologics discovery, but successful technology transfer and customer adoption are required to justify dilution and future royalties.

Capacity and infrastructure investment continued through automation, $27.6M of YTD capex, and a 33,000-square-foot South San Francisco lease expansion beginning in September 2026. The lease runs through June 2036, starts at ≈$0.5M monthly rent with 3% annual increases, and includes $24.4M of landlord-funded improvements; it supports growth but raises fixed costs ahead of proven profitability.

Risk Assessment

• Profitability and execution: YTD operating loss widened to $115.0M because SG&A growth outpaced revenue, so continued top-line expansion without expense leverage could prolong losses and reduce strategic flexibility.
• Liquidity and dilution: Cash and investments declined $65.6M since fiscal year-end; the $200.0M ATM improves financing access but transfers runway risk to shareholders through potential issuance.
• Cost and margin pressure: Q3 gross margin slipped to 52.8% as customer mix offset scale benefits; shipment growth that fails to improve unit economics would weaken the core margin-expansion thesis.
• Strategic investment concentration: Maximum exposure to unconsolidated variable-interest entities reached $90.0M, including $68.1M of private-company investments and the Invenra arrangement; illiquidity, valuation uncertainty, or technology-transfer failure could impair returns.
• Fixed commitments: $93.6M of operating lease liabilities and the expanded facility’s escalating rent increase the cost base before the business reaches breakeven.
• Litigation: Accrued litigation liabilities reached $19.7M, including a $17.1M securities settlement expected to be mostly insurer-funded; final court approval and insurance recovery remain execution points.
• Market and concentration exposure: The Americas generated 65% of Q3 revenue, while management reported no material change in interest-rate, FX, or other market risks; regional or funding-market disruption could still affect demand and liquidity.

This 10-Q lists no risk factors of its own and refers to the annual report. The risks above come from the rest of this filing. Full list: the company's 10-Ks on SEC.

Strategic Outlook and Investor Actionables

Twist is building a broader synthetic-biology and biologics-discovery platform, with therapeutics, higher gene volumes, automation, and the Invenra technology offering multiple paths to growth. The near-term question is no longer demand generation alone, but whether management can slow SG&A growth, preserve gross margin, and reduce cash consumption before additional equity becomes necessary.

• Operating leverage: Monitor Q4 SG&A growth and operating loss; confirmation requires expenses growing below revenue and a sequentially narrower loss.
• Unit economics: Monitor gross margin against 52.8% and revenue growth relative to shipment growth; rising margin alongside high volumes would validate automation and process savings.
• Funding runway: Monitor combined cash and investments, operating cash burn, capex, and ATM usage; accelerating burn or material share issuance would weaken the thesis through financing dependence and dilution.